Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis

Quality of Life Research

Volumn 12, Issue 5, 2003, Pages 565-574

  Green, Colin ^a   Kiebert, G ^b   Murphy, C ^c   Mitchell, J D ^d   O'Brien, M ^d   Burrell, A ^e   Leigh, P N ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b MEDTAP International   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ROYAL PRESTON HOSPITAL   (United Kingdom)

^e Aventis Pharma Ltd   (United Kingdom)

Author keywords

EQ 5D; Health state valuation; Motor neurone disease; Quality of life; Standard gamble

Indexed keywords

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; EXERCISE; FEMALE; HEALTH STATUS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MOTOR NEURON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VISUAL ANALOG SCALE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0041353525     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025052609818     Document Type: Article

References (34)

1. Riviere M, Meininger P, Zeisser P, et al. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998; 55: 526-528.
2. Donaghy M. The motor neurone diseases. In: Wetherall DJ, Ledingham JCG, Warrell DA (eds), Oxford Textbook of Medicine, 3rd, edn. Vol. 3. Oxford: Oxford University Press, 4087-4090.
3. Bernat JL, Vincent FM. Neurology. Oradell, New Jersey: Medical Economics Books, 1987.
4. Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 1989; 12: 833-841.
5. Norris F, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurl Sci 1993; 118: 48-55.
6. Benzimon G, Lacomblez L, Meininger V and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Eng J Med 1994; 330: 585-591.
7. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-1431.
8. Shields RK, Ruhland JL, Ross MA, et al. Analysis of health-related quality of life and muscle impairment in individuals with amyotrophic lateral sclerosis using the medical outcome survey and the Tufts Quantitative Neuromuscular Exam. Arch Phys Med Rehabilit 1998; 79: 855-862.
9. Damiano AM, Patrick DL, Guzman GI, et al. Measurement of health-related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies. Med Care 1999; 37: 15-26.
10. Green C, Brazier J, Deverill M. Valuing health-related quality of life: A review of health state valuation techniques. PharmacoEconomics 2000; 17: 151-165.
11. Jenkinson C, Fitzpatrick R, Brennan C, Swash M. Evidence for the validity and reliability of the ALS assessment questionnaire: The ALSAQ-40. ALS Motor Neuron Disorders 1999; 1: 33-40.
12. The EuroQol Group. EuroQol - a new facility for the measurement of health related quality of life. Health Policy 1990; 16: 199-208.
13. Kind P. The EuroQol instrument: An index of health-related quality of life. In: Spilker B, (ed), Quality of Life and PharmacoEconomics in Clinical Trials. Philadelphia: Lippincott Raven, 1996.
14. Williams A. A social tariff for EuroQol: Results from a UK general population survey. York Centre for Health Economics Discussion Paper No. 138. University of York, 1996.
15. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11): 1095-1108.
16. Von Neumann J, Morgenstern O. Theories of Games and Economic Behavior. New York: Wiley, 1953.
17. Torrance, G.W. Measurement of health state utilities for economic appraisal: A review. J Health Econ 1986; 5: 1-30.
18. Llewellyn-Thomas HA, Thiel ED, McGreal MJ. Cancer patients' evaluations of their current health states: The influence of expectations, comparisons, actual health status and mood. Med Dec Making 1992; 12: 115-122.
19. Ramsey SD, Patrick DL, Lewis S, et al. Improvement in quality of life after lung transplantation: A preliminary study. J Heart Lung Transplant 1995; 14: 870-877.
20. Furlong W, Feeny D, Torrance GW, Barr R, Horsman J. Guide to design and development of health-state utility instrumentation, CHEPA Working Paper, McMaster University, Hamilton, Ontario, Canada, 1989.
21. Jenkinson, C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neuron disease: The ALSAQ-40. J Neurol 1999; 246: III/16-III21.
22. Dolan P, Gudex C, Kind P, et al. Valuing health states: A comparison of methods. J Health Econ 1996; 15: 209-231.
23. Richardson J. Cost utility analysis: What should be measured? Soc Sci Med 1994; 39: 7-21.
24. Brazier JE, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. NHS Health Technol Assess 1999; 3 (9).
25. Nord E. Methods for quality adjustment of life years. Soc Sci Med 1992; 34: 559-569.
26. Loomes G, McKenzie L. The use of QALYs in health care decision making. Soc Sci Med 1989; 28: 299-308.
27. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chron Dis 1978; 31: 697-704.
28. Boyd NF, Sutherland HJ, Heasman KZ, Tritchler DL, Cummings BJ. Whose utilities for decision analysis? Med Decis Making 1990; 10: 58-67.
29. Hurst NP, Jobanputra P, Hunter M, Lambert M, Lockhead A, Brown H. Validity of EuroQol-ageneric health status instrument-in patients with rheumatoid arthritis. B. J Rheum 1994; 24: 973-980.
30. Jenkinson C, Gray A, Doll H, Lawrence K, Keoghane S, Layte R. Evaluation of index and profile measures of health status in a randomized controlled trial: Comparison of the Medical Outcomes Study 36-item short form health survey, EuroQol and disease specific measures. Med Care 1997; 35: 1109-1118.
31. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds), Cost Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
32. Nord E, Pinto JL, Richardson G, Menzel P, Ubel P. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ 1999; 8: 25-39.
33. Dolan P. Whose preferences count? Med Dec Making 1999; 482-486.
34. Froberg DG, Kane RL. Methodology for measuring health-state preferences-II: Scaling methods. J Clin Epidemiol 1989; 42: 459-471.